Fig. 1From: Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trialsTime to death since onset of first investigator-reported acute exacerbation reported as a serious adverse event, first acute exacerbation reported as a non-serious adverse event, and in patients with no acute exacerbation. Thirteen patients with no acute exacerbation died beyond day 372Back to article page